|Djamila L Ghafuri, MD, MPH|
|Michael R DeBaun, MD, MPH|
1 United States site
1 Nigeria site
16 to 26 Years
16 Years - 26 Years
Patients with hemoglobin S-S or Sβ0 thalassemia confirmed by hemoglobin electrophoresis or High-Performance Liquid Chromatography (HPLC);
Participant is 16 through 25 years of age;
Informed consent from participants above 18 years, and informed consent from a parent or legal guardian and assent of participants aged < 18 years (assessment can take place up until the 26th birthday); Participant resides within an hour driving distance from the medical center to facilitate weekly phone calls between the scheduled monthly clinic visits; Participant is willing to be enrolled and followed for the duration of the study.
Young adults with co-morbidities that may have an impact on neurological status, such as epilepsy;
Young adults enrolled in clinical trials upon entry;
Participants with an implanted defibrillator or certain other implanted electronic or metallic devices contraindicated for MRI;
Young adults with known HIV diagnosis;
Any other condition or chronic illness, which in the opinion of the site’s Principal Investigator (PI) makes participation ill-advised or unsafe.